← All indications
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.
Drugs by status
Approved for this indication (3)
Phase 4 trials (15)
- bupropion
- indocyanine green
- darbepoetin beta
- sargramostim
- hepatitis b vaccine (recombinant)
- human papillomavirus 9-valent vaccine, recombinant
- Filgrastim
- kang fu
- human fibrin
- hpv 16/18 vaccine
- nicotine
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- cisplatin
- lapatinib
Phase 3 trials (85)
- vincristine
- oxaliplatin
- ipilimumab
- diindolylmethane
- shr-1701
- prednisolone
- n-(4-hydroxyphenyl)all-trans retinamide
- sodium copper chlorophyllin
- famitinib
- pemetrexed
- F520
- lb4330
- bleomycin
- cetirizine
- vinblastine
- hlx10
- tropisetron
- diphenhydramine
- endostatin
- ondansetron
- aprepitant
- z-100
- docetaxel
- tegafur
- nelfinavir
- dalteparin
- urea
- fludeoxyglucose f-18
- lactose
- lb1410
- +55 more
Phase 2 trials (280)
- hetrombopag olamine
- bgb-a1217
- dostarlimab
- rc48-adc
- cediranib
- vorinostat
- dl-2-(difluoromethyl) ornithine
- capecitabine
- young tumor infiltrating lymphocytes
- vitamin d3
- avelumab
- aminolevulinic acid
- xnw28012
- pertuzumab
- bemarituzumab
- sacituzumab govitecan
- mapatumumab
- chidamide
- glycyrrhizin
- oc-001
- zimberelimab
- nogapendekin alfa inbakicept
- np137
- eribulin
- temozolomide
- trilaciclib
- sctil
- xmab20717
- tariquidar
- 13c-pyruvate
- +250 more
Phase 1 trials (130)
- mt-8421
- ac-aky-1189
- trivehexin
- tmtp1
- allogeneic natural killer cells
- phn-010
- imgn151
- abi-1968
- ly4052031
- fapi-46
- tqb2858
- autologous apd-l1 armored anti-cd22 car t cells
- kk-lc-1 tcr-t cells
- tsc-203-a0201
- cu-aky-1189
- qbs10072s
- idov-immune
- bs-006
- hfb200301
- slv-154
- hydrogen peroxide
- xb002
- atv-1601
- vmd-928
- 124i-iodo-azomycin galacto-pyranoside
- incagn02385
- fentanyl
- flubhpve6e7
- ly4101174
- sgn-b6a
- +100 more
Other trials (32)
- varenicline
- technetium tc-99m sulfur colloid kit
- lidocaine
- ropivacaine
- tretinoin
- trichloroacetic acid
- misoprostol
- tranexamic acid
- pngvl4a-crt/e7
- omega-3 fatty acids
- isosulfan blue
- propranolol
- remifentanil
- fish oil
- 68ga-nodaga-e(c[rgdyk])2
- cin2/3
- acetic acid
- sitosterols
- piperine
- [18f]f-resca-t4
- gadopenteate dimeglumine
- gx-i7
- ga-nota-rt4
- desflurane
- butorphanol
- axitinib
- hydromorphone
- cobalt chloride co-60
- [68ga]ga-nota-t4
- autologous blood
- +2 more
Organizations
Organization Involved with Phase 4 Indications (30)
- Merck
- International Agency for Research on Cancer
- Medical Research Council
- National Cancer Institute (NCI)
- National Institute for Medical Research, Tanzania
- Cancer Prevention and Research Institute, Italy
- University of London
- Duke University
- Temple University
- Georgetown University
- German Cancer Research Center
- Tata Memorial Hospital
- University of Florence
- University of Ulsan
- All India Institute of Medical Sciences
- MNJ Cancer Hospital Hyderabad
- Jehangir Clinical Development Centre Pvt. Ltd.
- University of Reims
- Gujarat Cancer & Research Institute
- Martin Luther University
- Istituto Toscano Tumori
- AGO Germany
- Rajiv Gandhi University of Health Sciences
- Ocean Road Cancer Institute, Tanzania
- International Union Against Cancer, Switzerland
- Cancer Foundation of India
- Christian Fellowship Community Health Centre
- People's Liberation Army of China
- Centers for Disease Control and Prevention (CDC)
- Chinese Academy of Medical Sciences
Organization Involved with Phase 3 Indications (134)
- Zeria Pharmaceutical
- Regeneron
- Celgene
- Advaxis, Inc.
- AstraZeneca
- Eli Lilly
- Sanofi
- Biocad
- GlaxoSmithKline
- Otsuka
- The EMMES Corporation
- International Atomic Energy Agency
- Fondazione Giovanni Pascale
- Huazhong University of Science and Technology
- Air Force Military Medical University, China
- University of Arizona
- Canadian Cancer Trials Group
- Cancer Research UK
- Chang Gung University
- Eastern Cooperative Oncology Group
- Gynecologic Oncology Group
- Hacettepe University
- Harbin Medical University
- Indiana University
- Institut de Cancérologie de Lorraine
- Institut fuer Frauengesundheit
- Jilin Provincial Tumor Hospital
- Jilin University
- Korea Cancer Center Hospital
- Kaiser Permanente
- +104 more
Organization Involved with Phase 2 Indications (197)
- Pierre Fabre
- Human Genome Sciences
- Daiichi Sankyo
- Seattle Genetics
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Genmab
- Roche
- Advenchen Laboratories, LLC
- Imclone
- Immunomedics
- Merck Serono
- Exelixis
- Genentech
- Merck KGaA
- Aventis
- Pfizer
- Siemens
- Novartis
- Bayer
- BeOne Medicines
- BIND Therapeutics
- Biotech Pharmaceutical Co., Ltd.
- Catalysis SL
- Farmoquimica S.A.
- Gradalis, Inc.
- Hengrui Therapeutics, Inc.
- Immunitor LLC
- Innovent Biologics (Suzhou) Co. Ltd.
- Inovio Pharmaceuticals
- +167 more
Organization Involved with Phase 1 Indications (39)
- MedImmune
- Wyeth
- Cellid Co., Ltd.
- Hebei Senlang Biotechnology Inc., Ltd.
- Hookipa Biotech
- Mithra Pharmaceuticals
- Sinphar Pharmaceutical Co., Ltd
- Preventive Oncology International, Inc.
- University of Pittsburgh
- Hebei University
- Augusta University
- Cancer and Leukemia Group B (CALGB)
- Ohio State University
- University of The West Indies
- Tufts University
- Thomas Jefferson University
- University of Tennessee
- University of Bordeaux
- William Marsh Rice University
- University of Chicago
- University of Copenhagen
- Xencor
- National Taiwan University
- Accord Research
- City of Hope National Medical Center
- Lee's Pharmaceutical
- University of Texas, Galveston
- Instituto Nacional de Enfermadades Neoplasticas (INEN)
- YRG Care
- Erasmus University Rotterdam
- +9 more
Organization Involved with Other Experimental Indications (15)
- Jhpiego
- Brazilian National Cancer Institute
- Campus Bio-Medico University
- Centre Leon Berard
- Chulalongkorn University
- Eastern Virginia Medical School
- University of Kansas
- University of Michigan
- University of British Columbia
- The University of Hong Kong
- Cancer Institute Foundation, Phillipines
- University of Erlangen-Nuremberg
- Hôtel Dieu de France Hospital
- National Institute of Cancerología
- Campus Biomedico of Rome